{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:30:23Z","timestamp":1770071423404,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.vaccine.2011.07.025","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T18:53:21Z","timestamp":1311447201000},"page":"7067-7074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01"],"prefix":"10.1016","volume":"29","author":[{"given":"Anders","family":"Fomsgaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregers","family":"Gram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Kromann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Vibe","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.07.025_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nri2674","article-title":"The immune response during acute HIV-1 infection: clues for vaccine development","volume":"10","author":"McMichael","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2011.07.025_bib0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nat Med"},{"issue":"December (Suppl. 2)","key":"10.1016\/j.vaccine.2011.07.025_bib0015","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1097\/QAI.0b013e3181baec7c","article-title":"Are we on course for reporting on the millennium development goals in 2015?","volume":"52","author":"Rugg","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2011.07.025_bib0020","unstructured":"UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010; 2010 [cited; Available from: www.UNAIDS.org\/globalreport\/global_report.htm.]"},{"issue":"July (5681)","key":"10.1016\/j.vaccine.2011.07.025_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1126\/science.1100600","article-title":"Therapeutic vaccines for chronic infections","volume":"305","author":"Autran","year":"2004","journal-title":"Science"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2011.07.025_bib0030","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1147","article-title":"Therapeutic dendritic-cell vaccine for chronic HIV-1 infection","volume":"10","author":"Lu","year":"2004","journal-title":"Nat Med"},{"issue":"September (Pt. 9)","key":"10.1016\/j.vaccine.2011.07.025_bib0035","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1099\/vir.0.19152-0","article-title":"Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes","volume":"84","author":"Corbet","year":"2003","journal-title":"J Gen Virol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.07.025_bib0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1600-0463.2007.apm_595.x","article-title":"Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals","volume":"115","author":"Thorn","year":"2007","journal-title":"APMIS"},{"issue":"July (11)","key":"10.1016\/j.vaccine.2011.07.025_bib0045","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/QAD.0b013e32832d9b00","article-title":"Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes","volume":"23","author":"Kloverpris","year":"2009","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.vaccine.2011.07.025_bib0050","doi-asserted-by":"crossref","first-page":"e3116","DOI":"10.1371\/journal.pone.0003116","article-title":"Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements","volume":"3","author":"Agger","year":"2008","journal-title":"PLoS One"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.07.025_bib0055","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1211\/jpp.58.6.0009","article-title":"A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice","volume":"58","author":"Vangala","year":"2006","journal-title":"J Pharm Pharmacol"},{"issue":"December (1\u20132)","key":"10.1016\/j.vaccine.2011.07.025_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbamem.2005.10.011","article-title":"Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6\u2032-dibehenate)\u2014a novel adjuvant inducing both strong CMI and antibody responses","volume":"1718","author":"Davidsen","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2011.07.025_bib0065","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2567.2007.02560.x","article-title":"The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes","volume":"121","author":"Korsholm","year":"2007","journal-title":"Immunology"},{"issue":"October (5)","key":"10.1016\/j.vaccine.2011.07.025_bib0070","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/14760584.6.5.785","article-title":"Cationic liposomes as vaccine adjuvants","volume":"6","author":"Christensen","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2011.07.025_bib0075","doi-asserted-by":"crossref","first-page":"e6950","DOI":"10.1371\/journal.pone.0006950","article-title":"A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice","volume":"4","author":"Gram","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2011.07.025_bib0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/08982100902726820","article-title":"Liposome-based cationic adjuvant formulations (CAF): past, present, and future","volume":"19","author":"Christensen","year":"2009","journal-title":"J Liposome Res"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2011.07.025_bib0085","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.4049\/jimmunol.180.7.5092","article-title":"Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes","volume":"180","author":"Perez","year":"2008","journal-title":"J Immunol"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2011.07.025_bib0090","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1128\/JVI.77.4.2663-2674.2003","article-title":"Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection","volume":"77","author":"Malhotra","year":"2003","journal-title":"J Virol"},{"issue":"May (9)","key":"10.1016\/j.vaccine.2011.07.025_bib0095","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1128\/JVI.75.9.4195-4207.2001","article-title":"Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes","volume":"75","author":"Wilson","year":"2001","journal-title":"J Virol"},{"issue":"June (19)","key":"10.1016\/j.vaccine.2011.07.025_bib0100","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.vaccine.2003.11.061","article-title":"Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE)","volume":"22","author":"Alexander","year":"2004","journal-title":"Vaccine"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2011.07.025_bib0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0952-7915(00)00103-5","article-title":"The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1","volume":"12","author":"Altfeld","year":"2000","journal-title":"Curr Opin Immunol"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2011.07.025_bib0110","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.1073\/pnas.1100567108","article-title":"CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input","volume":"108","author":"Kumamoto","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.07.025_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2172-9-1","article-title":"HLA class I supertypes: a revised and updated classification","volume":"9","author":"Sidney","year":"2008","journal-title":"BMC Immunol"},{"issue":"May (25\u201326)","key":"10.1016\/j.vaccine.2011.07.025_bib0120","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1016\/j.vaccine.2009.01.090","article-title":"Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up","volume":"27","author":"Longo","year":"2009","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2011.07.025_bib0125","doi-asserted-by":"crossref","first-page":"e13540","DOI":"10.1371\/journal.pone.0013540","article-title":"Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART","volume":"5","author":"Ensoli","year":"2010","journal-title":"PLoS One"},{"issue":"May (20)","key":"10.1016\/j.vaccine.2011.07.025_bib0130","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.vaccine.2006.03.009","article-title":"Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects","volume":"24","author":"Firbas","year":"2006","journal-title":"Vaccine"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2011.07.025_bib0135","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1002\/eji.200425463","article-title":"A mouse model of human adaptive immune functions: HLA-A2.1-\/HLA-DR1-transgenic H-2 class I-\/class II-knockout mice","volume":"34","author":"Pajot","year":"2004","journal-title":"Eur J Immunol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.07.025_bib0140","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","article-title":"Response definition criteria for ELISPOT assays revisited","volume":"59","author":"Moodie","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"November\u2013December (3)","key":"10.1016\/j.vaccine.2011.07.025_bib0145","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.vascn.2010.05.009","article-title":"The utility of the minipig as an animal model in regulatory toxicology","volume":"62","author":"Bode","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2011.07.025_bib0150","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1084\/jem.185.12.2043","article-title":"HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice","volume":"185","author":"Pascolo","year":"1997","journal-title":"J Exp Med"},{"issue":"February (1\u20132)","key":"10.1016\/j.vaccine.2011.07.025_bib0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jim.2010.11.002","article-title":"Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine","volume":"365","author":"Cobb","year":"2011","journal-title":"J Immunol Methods"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.07.025_bib0160","doi-asserted-by":"crossref","first-page":"e1000055","DOI":"10.1371\/journal.ppat.1000055","article-title":"Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood","volume":"4","author":"De Rose","year":"2008","journal-title":"PLoS Pathog"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2011.07.025_bib0165","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1128\/JVI.79.5.3052-3062.2005","article-title":"Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons","volume":"79","author":"Huang","year":"2005","journal-title":"J Virol"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2011.07.025_bib0170","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00126334-200308010-00003","article-title":"Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities","volume":"33","author":"Sabbaj","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2011.07.025_bib0175","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1073\/pnas.90.6.2217","article-title":"An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins","volume":"90","author":"Zhang","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.07.025_bib0180","series-title":"HIV Molecular Immunology Database","article-title":"Systematic identification of optimal HIV-1 CTL epitopes, 1997","author":"Brander","year":"1997"},{"issue":"September (10)","key":"10.1016\/j.vaccine.2011.07.025_bib0185","first-page":"1075","article-title":"Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules","volume":"10","author":"Shiga","year":"1996","journal-title":"AIDS"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11010462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11010462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:20:58Z","timestamp":1759400458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11010462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":37,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0264410X11010462"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}